Cardiff Oncology (NASDAQ:CRDF) Given New $6.00 Price Target at Piper Sandler

Cardiff Oncology (NASDAQ:CRDF) had its target price lowered by Piper Sandler from $10.00 to $6.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other equities analysts have also commented on CRDF. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Cardiff Oncology in a report on Wednesday, January 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, January 21st. Finally, Noble Financial initiated coverage on Cardiff Oncology in a research report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.10.

Cardiff Oncology Trading Up 12.4%

NASDAQ:CRDF opened at $1.91 on Wednesday. The stock’s 50-day moving average is $2.35 and its 200-day moving average is $2.25. Cardiff Oncology has a 1-year low of $1.48 and a 1-year high of $4.56. The stock has a market cap of $128.66 million, a P/E ratio of -2.77 and a beta of 1.33.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Tuesday, February 24th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.07. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 77.17%. The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, equities analysts forecast that Cardiff Oncology will post -0.99 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Cardiff Oncology in the 4th quarter valued at about $108,000. XTX Topco Ltd increased its holdings in Cardiff Oncology by 40.5% in the fourth quarter. XTX Topco Ltd now owns 219,357 shares of the company’s stock worth $616,000 after purchasing an additional 63,196 shares in the last quarter. Millennium Management LLC lifted its stake in Cardiff Oncology by 441.5% in the fourth quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock valued at $546,000 after buying an additional 158,519 shares during the period. Laurion Capital Management LP boosted its holdings in shares of Cardiff Oncology by 7.3% during the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock worth $7,437,000 after buying an additional 180,866 shares in the last quarter. Finally, Tamar Securities LLC bought a new position in shares of Cardiff Oncology during the 4th quarter worth approximately $32,000. 16.29% of the stock is owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.